Antiarrhythmic effect of acute oxygen-ozone administration to rats.
The antiarrhythmic effects of 100; 150; and 300microg/kg i.p. oxygen/ozone mixture were tested on arrhythmias induced by i) ischemia; ii) ischemia/reperfusion; iii) aconitine (15microg/kg/i.v.); potassium chloride (1.5% i.v.) in rats. 25min of cardiac left descending coronary artery ischemia caused severe incidence of ventricular tachycardia, ventricular fibrillation and mortality. These were significantly reduced by pre-treatment of rats with oxygen/ozone mixture at doses of 150 and 300microg/kg. In separate experiments using a protocol of 5min ischemia followed by 8min reperfusion this caused arrhythmias starting within 6+/-1s. The incidence of ventricular tachycardia was 100%, while ventricular fibrillation occurred in 75% of the animals and lasted 85+/-14s. The mortality was 62.5%. These figures were significantly (P<0.01) reduced in animals treated with 150microg/kg oxygen/ozone and a substantial increase observed with 300microg/kg, whilst not affected by the lower dose of 100microg/kg. 150 and 300microg/kg oxygen/ozone prolonged the onset time for the appearance of arrhythmias induced by aconitine (300microg/kg oxygen/ozone, approximately 81% longer). Oxygen/ozone also reduced the ventricular tachycardia duration, ventricular fibrillation incidence, arrhythmia score, and increased the rat's survival rate. As for example, this latter was increased from 25% (aconitine) to 50% (aconitine+oxygen/ozone 150microg/kg). 100microg/kg oxygen/ozone was without effect. None of the oxygen/ozone doses affected the arrhythmias caused by potassium chloride 1.5% i.v. All the oxygen/ozone antiarrhythmic effects were similar to those observed with lidocaine (1.5mg/kg i.v.). In conclusion, oxygen/ozone has antiarrhythmic effects against arrhythmias caused by aconitine, myocardial ischemia and ischemia/reperfusion.
Di Filippo
Clara
C
Department of Experimental Medicine, Section of Pharmacology L. Donatelli, 2nd University of Naples, Italy.
Cervone
Carmela
C
Rossi
Claudia
C
di Ronza
Cristina
C
Marfella
Raffaele
R
Capodanno
Paola
P
Luongo
Carlo
C
Rossi
Francesco
F
D'Amico
Michele
M
D000157:Aconitine / Q000633:toxicity; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage* / Q000494:pharmacology* / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D017202:Myocardial Ischemia / Q000150:complications / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D010100:Oxygen / Q000008:administration & dosage* / Q000494:pharmacology* / Q000627:therapeutic use; D010126:Ozone / Q000008:administration & dosage* / Q000494:pharmacology* / Q000627:therapeutic use; D011189:Potassium Chloride / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000150:complications / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology
D000889:Anti-Arrhythmia Agents; D011189:Potassium Chloride; D010126:Ozone; D010100:Oxygen; D000157:Aconitine